International Edition
Latest News
Health

Pancreatic Cancer Pill Clears Tumours in One in 12 Patients, Trial Shows

Advanced pancreatic cancer treatment has entered a new phase as clinical trials show a targeted daily pill can shrink or entirely clear aggressive tumours. In one in 12 patients given the drug daraxonrasib alongside standard chemotherapy, the cancer…

Pancreatic Cancer Pill Clears Tumours in One in 12 Patients, Trial Shows

Advanced pancreatic cancer treatment has entered a new phase as clinical trials show a targeted daily pill can shrink or entirely clear aggressive tumours.

In one in 12 patients given the drug daraxonrasib alongside standard chemotherapy, the cancer became undetectable on scans, according to trial findings reported by The Guardian.

Researchers monitored 61 patients with advanced metastatic pancreatic adenocarcinoma who had recently been diagnosed. Tumours stopped growing in 90.2% of participants, while over 60% saw their tumours shrink or disappear entirely during a median follow-up period of 18.3 months, Yahoo Finance Australia reported.

Medical professionals hailed the results as a major shift for a disease with notoriously poor prognoses. Half of all patients diagnosed with pancreatic cancer die within three months, and only about 3% survive for five years once the disease spreads to other organs, figures from The Guardian show.

“This is the closest to cure,” said Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, who presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. Park added that he had never seen so many tumours disappear in patients whose cancer had spread.

How Daraxonrasib Targets Mutant Proteins

Daraxonrasib is a KRAS inhibitor treatment designed to lock onto and shut off mutated proteins that drive tumour growth. More than nine in 10 pancreatic tumours carry a mutation in the gene that makes KRAS, a protein often nicknamed the “Death Star” because pharmaceutical researchers have historically found it nearly impossible to attack, The Telegraph reported.

The genetic mutation forces the protein to send constant signals telling cancer cells to multiply. By binding directly to the protein, daraxonrasib blocks those signals and starves the tumour of growth instructions.

CT scans before and after treatment
Photo: BBC

The drug has already received regulatory backing in the United States and secured approval from the European Commission as a monotherapy for adult patients who received prior systemic therapy, Yahoo Finance reported. The latest trials test its efficacy when combined directly with standard chemotherapy drugs gemcitabine and nab-paclitaxel.

“These results are exciting because they show the combined treatment could potentially significantly improve patients’ overall survival, as well as the time before tumours start to grow again,” said Prof Elena Garralda, chair of the Barcelona symposium and co-director of the clinical research programme at the Vall d’Hebron Institute of Oncology, as reported by BBC.

Trial Data Shows Improved Survival Rates

Data from the phase one and two trials indicate that 76.6% of patients were still alive one year after starting the combination treatment. This compares favorably with historical survival rates of 40% to 45% for patients receiving chemotherapy alone, as noted by LBC.

Earlier investigations into daraxonrasib also demonstrated significant life-extending benefits. Patients given the drug in previous single-agent trials lived a median of 13.2 months compared with 6.7 months for those on chemotherapy alone, according to findings cited by The Telegraph.

The median time before tumours began progressing again or patients died reached 12.8 months in the latest combination study. Researchers note that cancer can eventually develop resistance to targeted therapies, making longer-term observation essential.

“Cancer can come back and even if scans show there is no sign of it, you don’t necessarily know you are cancer-free until more time has passed,” said Dr Godfrey.

Pancreatic Cancer Pill Clears Tumours in One in 12 Patients, Trial Shows
Photo: The Telegraph

Wider Implications for Cancer Treatment

Medical experts believe the success of KRAS inhibition in pancreatic tissue could eventually pave the way for treating other malignancies. Dozens of other common cancers, including lung and ovarian tumours, carry similar RAS gene mutations that drive uncontrolled cell division.

Michelle Mitchell, chief executive of Cancer Research UK, described the developments as a major turning point. “This is the biggest leap forward we’ve seen in decades for pancreatic cancer patients and could offer real hope to people facing one of the deadliest and most difficult-to-treat cancers,” she told The Guardian.

In the United Kingdom, approximately 11,500 people receive a pancreatic cancer diagnosis each year, with around 10,200 dying from the disease, according to Cancer Research UK statistics published by BBC. High-profile figures, including actor Alan Rickman, have succumbed to the illness shortly after diagnosis.

Pancreatic Cancer Trial Metrics and Comparisons
Metric Daraxonrasib Combination Standard Chemotherapy
One-Year Survival Rate 76.6% 40% – 45%
Tumour Growth Control 90.2% of patients Lower historical rates
Median Progression-Free Survival 12.8 months 5 – 6 months

Next Steps for Patient Access

While oncologists view the early data as highly promising, health authorities emphasize that larger clinical evaluations are required before routine administration can begin. A global Phase III trial named RASolute-303 is currently underway to compare the daraxonrasib and chemotherapy combination directly against chemotherapy alone, according to EurekAlert!.

Regional health authorities in Europe are already examining pathways for wider distribution. In Italy, the Lombardy Region announced plans to support patient associations aiming to secure free access to daraxonrasib following its European regulatory approvals, Il Sole 24 ORE reported.

Pancreatic Cancer Pill Clears Tumours in One in 12 Patients, Trial Shows
Photo: Yahoo Finance Australia

Researchers caution that despite the deep responses observed in scans, patients must be followed for extended periods to confirm true remission rates. “Further research is needed to look at how this drug could be used alongside other therapies to give patients the best chance of beating the disease,” Mitchell told LBC.

Frequently Asked Questions

Is daraxonrasib available on the NHS in the UK?

The treatment is not yet available for routine use on the NHS. Cancer Research UK notes that more clinical trials are required before health authorities can formally assess the combination therapy for national health service deployment.

What are the common symptoms of pancreatic cancer?

Symptoms identified by health organizations include jaundice, itchy skin, dark urine, pale stools, unexplained weight loss, persistent fatigue, and a high temperature.

How does daraxonrasib differ from standard chemotherapy?

While standard chemotherapy attacks rapidly dividing cells indiscriminately, daraxonrasib is a targeted therapy designed specifically to lock onto and shut off mutant KRAS proteins that signal pancreatic cancer cells to grow.

Memorial Sloan Kettering Cancer Center traces its origins to New York Cancer Hospital, founded in 1884 on Manhattan’s Upper West Side by a group that included John Jacob Astor III. In 1902, Arabella Huntington established the nation’s first dedicated cancer research fund there with a US$100,000 bequest.

The institution pioneered early immunotherapy under surgeon William B. Coley and launched the first U.S. fellowship training program in oncology in 1927. A 1980 merger combined Memorial Hospital with the adjacent Sloan-Kettering Institute for Cancer Research, created in 1945 through a $4 million gift from General Motors chairman Alfred P. Sloan and engineer Charles F. Kettering.

Are other cancers being treated with this drug?

Clinical investigations are examining whether KRAS inhibitors can benefit patients with other malignancies, such as lung and ovarian cancers, which often share similar genetic mutations.

About the author: Health Desk

Health Desk at Archynewsy.